Dr Toru Kondo

  • Visiting Clinical Research Fellow, Affiliate (School of Cardiovascular & Metabolic Health)

Publications

List by: Type | Date

Jump to: 2022
Number of items: 7.

2022

Adamson, C. et al. (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European Heart Journal, (doi: 10.1093/eurheartj/ehac481) (PMID:36029309) (Early Online Publication)

Butt, J. H. et al. (2022) Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER. Journal of the American College of Cardiology, (doi: 10.1016/j.jacc.2022.08.718) (PMID:36041668) (In Press)

Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (Early Online Publication)

Kondo, T. et al. (2022) Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. European Heart Journal, (doi: 10.1093/eurheartj/ehac487) (PMID:36017729) (Early Online Publication)

Pocock, S. J. et al. (2022) Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.2607) (PMID:35796209) (Early Online Publication)

Kondo, T., Jhund, P. S. and McMurray, J. J.V. (2022) Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose? European Journal of Heart Failure, 24(3), pp. 421-430. (doi: 10.1002/ejhf.2447) (PMID:35119172)

Kondo, T. and McMurray, J. J.V. (2022) Re-emergence of heart failure with a normal ejection fraction? European Heart Journal, 43(5), pp. 427-429. (doi: 10.1093/eurheartj/ehab828) (PMID:34878520)

This list was generated on Wed Oct 5 07:19:46 2022 BST.
Jump to: Articles
Number of items: 7.

Articles

Adamson, C. et al. (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European Heart Journal, (doi: 10.1093/eurheartj/ehac481) (PMID:36029309) (Early Online Publication)

Butt, J. H. et al. (2022) Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER. Journal of the American College of Cardiology, (doi: 10.1016/j.jacc.2022.08.718) (PMID:36041668) (In Press)

Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (Early Online Publication)

Kondo, T. et al. (2022) Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. European Heart Journal, (doi: 10.1093/eurheartj/ehac487) (PMID:36017729) (Early Online Publication)

Pocock, S. J. et al. (2022) Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.2607) (PMID:35796209) (Early Online Publication)

Kondo, T., Jhund, P. S. and McMurray, J. J.V. (2022) Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose? European Journal of Heart Failure, 24(3), pp. 421-430. (doi: 10.1002/ejhf.2447) (PMID:35119172)

Kondo, T. and McMurray, J. J.V. (2022) Re-emergence of heart failure with a normal ejection fraction? European Heart Journal, 43(5), pp. 427-429. (doi: 10.1093/eurheartj/ehab828) (PMID:34878520)

This list was generated on Wed Oct 5 07:19:46 2022 BST.